8-K: Arrowhead Pharmaceuticals Announces Fiscal Year 2025 First Quarter Results, Highlights FDA Acceptance of Plozasiran NDA

Arrowhead Pharmaceuticals reported its fiscal 2025 first-quarter results, featuring the FDA's acceptance of the plozasiran NDA and a significant collaboration agreement with Sarepta Therapeutics.

Summary

• Arrowhead Pharmaceuticals announced its fiscal 2025 first-quarter results, ending December 31, 2024.
• The company highlighted the FDA's acceptance of the New Drug Application (NDA) for investigational plozasiran for familial chylomicronemia syndrome (FCS).
• Arrowhead closed a licensing and collaboration agreement with Sarepta Therapeutics, receiving $825 million upfront.
• Phase 3 studies of plozasiran in severe hypertriglyceridemia are expected to be fully enrolled in 2025, with potential study completion in 2026.
• The company initiated Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7, both potential obesity treatments.
• First-quarter revenue was $2.5 million, compared to $3.551 million in the same period last year.
• The operating loss was $(161.412) million, compared to $(136.545) million in the prior year.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $(173.085) million, or $(1.39) per share diluted.
• As of December 31, 2024, cash, cash equivalents, and restricted cash totaled $53.889 million, with total cash resources of $552.935 million.
• The company is funded into 2028.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the FDA acceptance of the plozasiran NDA and the significant collaboration with Sarepta Therapeutics. However, the increased operating loss and net loss temper the overall sentiment.

Positives

• FDA acceptance of the plozasiran NDA represents a significant regulatory milestone.
• The collaboration with Sarepta Therapeutics provides substantial upfront funding and potential future revenue.
• Positive Phase 3 PALISADE study results support the efficacy of plozasiran.
• Initiation of Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7 expands the company's pipeline in the obesity area.
• The company is funded into 2028, providing financial stability for ongoing research and development.

Negatives

• First-quarter revenue decreased to $2.5 million from $3.551 million in the same period last year.
• The operating loss increased to $(161.412) million from $(136.545) million in the prior year.
• Net loss attributable to Arrowhead Pharmaceuticals, Inc. increased to $(173.085) million, or $(1.39) per share diluted.

Risks

• The success of plozasiran is dependent on FDA approval and successful commercialization.
• Clinical trials for ARO-INHBE and ARO-ALK7 are in early stages, and their success is not guaranteed.
• The company's financial performance is subject to fluctuations in revenue and expenses.
• The company's actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time.

Future Outlook

Arrowhead is well-positioned for growth with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years. Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026. The company sees emerging high-value potential in its obesity and CNS programs entering early clinical studies. Arrowhead is currently funded into 2028 with further cash runway potential with multiple wholly owned candidates providing opportunities for additional partnerships.

Management Comments

• Christopher Anzalone, Ph.D., President and CEO, stated that the company signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted the first NDA for investigational plozasiran, which was subsequently accepted for filing by the U.S. FDA.
• Christopher Anzalone, Ph.D., President and CEO, stated that the company is now well positioned for growth with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years.
• Christopher Anzalone, Ph.D., President and CEO, stated that the company sees emerging high-value potential in its obesity and CNS programs entering early clinical studies.
• Christopher Anzalone, Ph.D., President and CEO, stated that Arrowhead is currently funded into 2028 with further cash runway potential with multiple wholly owned candidates providing opportunities for additional partnerships.

Industry Context

Arrowhead's focus on RNAi therapeutics positions it within a competitive landscape of companies developing gene silencing technologies. The collaboration with Sarepta Therapeutics highlights the increasing interest in RNAi-based therapies for genetic diseases. The expansion into obesity treatments with ARO-INHBE and ARO-ALK7 reflects the growing market for weight management solutions.

Comparison to Industry Standards

• The $825 million upfront payment from Sarepta Therapeutics is a substantial deal compared to other licensing agreements in the RNAi therapeutics space.
• The potential for $10 billion in milestone payments is significant and reflects the high expectations for the collaboration.
• The Phase 3 PALISADE study results appear competitive with other triglyceride-lowering therapies in development.
• Arrowhead's cash runway into 2028 provides a longer period of financial stability compared to many other biotech companies of similar size.

Stakeholder Impact

• Shareholders will benefit from the upfront payment and potential future revenue from the Sarepta collaboration.
• Patients with familial chylomicronemia syndrome may benefit from the potential approval of plozasiran.
• Employees will benefit from the company's financial stability and growth prospects.
• The collaboration with Sarepta Therapeutics may create new opportunities for suppliers and partners.

Next Steps

• Advance plozasiran through the FDA approval process.
• Continue Phase 3 studies of plozasiran in severe hypertriglyceridemia.
• Advance Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7.
• Pursue additional partnerships for other pipeline candidates.

Key Dates